Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMHOTEP perioperative pembrolizumab in resectable MSI/dMMR or EBV-positive gastric tumors
2024-518127-30-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in colorectal cancer (CRC), rectal cancer, gastric cancer (GC) and 3 more, sponsored by Centre Léon Bérard. Primary endpoint: Complete pathological response rate. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
colorectal cancer (CRC)rectal cancergastric cancer (GC)esophagogastric junction canceresophageal cancer
Beyond the preview
Go deeper on 2024-518127-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518127-30-00.